Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|April 22, 2006
Immunostimulants revisited: focus on the pharmacology of RibomunylPierre Portalès, Jacques Clot
Alcohol and Alcoholism (Oxford, Oxfordshire)|October 23, 2004
Diminished CD4+ T cell surface CCR5 expression in alcoholic patientsPascal Perney, Pierre Portalès, Jacques Clot, et al.
Alcoholism, Clinical and Experimental Research|November 25, 2003
Specific alteration of peripheral cytotoxic cell perforin expression in alcoholic patients: a possible role in alcohol-related diseasesPascal Perney, Pierre Portalès, Pierre Corbeau, et al.
AIDS (London, England)|February 25, 2003
Perforin expression in T cells and virological response to PEG-interferon alpha2b in HIV-1 infectionPierre Portales, Jacques Reynes, Régine Rouzier-Panis, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 16, 2002
Cell surface CCR5 density determines the postentry efficiency of R5 HIV-1 infectionYea-Lih Lin, Clement Mettling, Pierre Portales, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 7, 2010
Pairwise comparison of isogenic HIV-1 viruses: R5 phenotype replicates more efficiently than X4 phenotype in primary CD4+ T cells expressing physiological levels of CXCR4Anne-Laure Fiser, Yea-Lih Lin, Pierre Portalès, et al.
AIDS (London, England)|February 25, 2003
Interferon-alpha restores HIV-induced alteration of natural killer cell perforin expression in vivoPierre Portales, Jacques Reynes, Valérie Pinet, et al.
AIDS (London, England)|January 16, 2008
The chemokine CCL5 regulates the in vivo cell surface expression of its receptor, CCR5Yea-Lih Lin, Clément Mettling, Pierre Portalès, et al.
Pageof 2